Five Point Four Times the Incidence, and Nobody Has Counted the Delay

A coin-shaped patch on the scalp or the face. Scaly at first, then flattening into something atrophic and paler in the middle with a darker rim. Where it sits on the scalp, the hair inside it goes and does not return.

Discoid lupus erythematosus is the most common form of chronic cutaneous lupus, and in the one population-based registry that stratified by race it is dramatically unequal.

The incidence ratio

The Georgia Lupus Registry did multiple-source case finding across dermatology practices, rheumatology practices, multispecialty facilities and dermatopathology reports, and counted primary chronic cutaneous lupus — that is, cutaneous disease in the absence of systemic lupus.

Age-adjusted incidence for definite DLE: 2.9 per 100,000 person-years.

Black to white incidence ratio: 5.4. Female to male: 3.1.

The authors summarize it as a three- to fivefold increased incidence in Black individuals. The absolute race-specific rates are not in the abstract, so anybody quoting separate per-100,000 figures by race from this study is inventing them.

One thing worth correcting while we are here. The commonly cited US incidence figure for cutaneous lupus comes from Olmsted County, Minnesota, 1965 to 2005, and was standardized to the US white population. It is a good study and it cannot speak to race at all, which does not stop it being cited as though it can.

And the Swedish national cohort, 1,088 patients, the largest of its kind, found mean age at onset of 54. DLE gets written about as a young woman’s disease. In the biggest register cohort, onset was in the mid-fifties — though register data captures people at specialist contact, which skews older.

What it costs, measured

Joseph and colleagues took 183 DLE patients — 112 Black, 71 non-Black — with recorded CLASI scores and ran the comparison.

CLASI has two halves. Activity is the live inflammation. Damage is dyspigmentation plus scarring: the part that does not go away.

Median damage score at baseline: 10.0 in Black patients, 6.0 in non-Black patients. Sixty-seven percent higher, p less than 0.001.

Adjusted odds ratios, Black against non-Black: scalp dyspigmentation 5.85. Ear dyspigmentation 2.89. Scarring alopecia 3.00. Any scalp involvement 2.54.

And dyspigmentation in any location: odds ratio 48.9.

Handle that last figure honestly. An odds ratio of forty-nine is a near-ceiling effect — dyspigmentation is close to universal in one group and uncommon in the other — rather than a precisely estimated risk. The confidence interval is not published and it will be enormous. The scalp figure of 5.85 and the scarring alopecia figure of 3.00 are the stable ones.

There is also a confound the authors name themselves. Damage measured at first specialist visit conflates biology with time. Patients who reach a specialty clinic later have had longer to accumulate damage, and this design cannot separate that from intrinsic pigmentary reactivity. Which is another way of saying the damage gap may be, in part, the delay gap made visible.

Why the hair does not come back

This is worth understanding because it determines everything about urgency.

In alopecia areata the immune attack concentrates at the anagen bulb and the stem cell pool in the bulge survives. Suppress the immune response and hair regrows. The loss is reversible.

In scalp DLE the injury is immune-complex and complement driven, and it sits in the upper follicle and the interfollicular epidermis — which is where the stem cell niche is. Destroy that and the follicle is replaced by a fibrous tract.

Once the follicle is gone there is no drug target left. Which is why time to treatment, not choice of drug, is the variable that decides the cosmetic outcome.

That is the mechanism and it is solid. The quantification is not. I went looking for a study relating duration of untreated DLE to probability of permanent alopecia — some threshold, some number of months — and there is not one. Every review asserts that early treatment prevents scarring. Nobody has measured it. So take the urgency seriously on mechanism, and treat any specific number of months you see quoted as unsourced.

There is an asymmetry inside the damage that matters too. The hyperpigmentation of active disease usually fades over months to years. The central hypopigmentation of a burnt-out plaque is frequently permanent, because the melanocytes went with the destroyed epidermis and follicle. The disfiguring half is the permanent half. That is clinically real and, again, no cohort has quantified repigmentation rates.

The absence that is the story

For hidradenitis suppurativa there is an entire diagnostic-delay literature. Mean years to diagnosis in four countries. Number of physicians seen first — 54 percent saw at least three, 15 percent saw at least ten. Average number of misdiagnoses per patient. Predictors of delay. Published, replicated, quotable.

For scalp DLE there is nothing equivalent. No misdiagnosis rate. No mean diagnostic delay. No count of how many clinicians a patient sees first.

The misdiagnosis pattern is described repeatedly in clinical reviews, and it is anatomically explicable — DLE and central centrifugal cicatricial alopecia converge on the same upper-follicle unit with different effector biology, which is exactly why they look alike on the crown of a Black woman’s scalp. Seborrheic dermatitis and tinea capitis sit on the same differential.

It has simply never been counted.

So the disease that disproportionately and permanently scars Black women’s scalps has no diagnostic-delay literature at all. That is not a finding I can quantify for you. It is a hole where a number should be, and I would rather name it than fill it with something plausible.

DLE is also a trap in the other direction. A thirteen-patient series of cutaneous follicle center lymphoma on the scalp and forehead lists discoid lupus among the initial diagnoses given. Scalp sarcoidosis lists it too. Things get called DLE that are not, and things that are DLE get called other things.

Does it become systemic lupus?

The honest answer is: sometimes, over a long time, and usually mildly — and the reported percentages disagree because they are measuring different things.

Olmsted County, 156 cutaneous lupus patients with forty years of records: 19 progressed to systemic lupus, a cumulative incidence of 19 percent at twenty years, with mean time to progression of 8.2 years.

A prospective Penn cohort of 77 patients: 17 percent met criteria for systemic lupus, mean time 8.03 years. Two independent cohorts agreeing almost exactly on the timing, which is the most reproducible number in this literature.

Now the part that deflates the scare. Of the thirteen Penn patients who crossed the threshold, one met only mucocutaneous criteria and three met mucocutaneous criteria plus antibodies. After a mean of 2.81 further years, only five of the thirteen had developed moderate to severe additional systemic disease.

The classification criteria for systemic lupus count discoid rash and photosensitivity. Which means a patient with bad skin disease and a positive antinuclear antibody can cross the line into “systemic lupus” without any new organ involvement at all. The authors’ conclusion: a small percentage of patients with cutaneous lupus eventually develop systemic lupus, and even if they do, most will have mild systemic disease.

The Swedish figure that circulates — 18 percent additional diagnoses — came from a maximum three-year register window and is a detection effect as much as a progression rate. It is not comparable to nineteen percent at twenty years, and it should never be quoted as “18 percent of DLE progresses.”

And a DLE-specific, race-stratified progression rate does not exist. Given the 5.4 times incidence and the damage findings, that is a real gap.

Hydroxychloroquine, honestly

It is first-line and it is described to patients as though it works.

The best DLE-specific data: 200 patients, median follow-up eight years. Adequate clinical response in 45.5 percent. Non-response in 42.5 percent. The authors’ conclusion is that long-term response occurred in fewer than half of patients.

Two dynamics from that study almost never get mentioned at the appointment.

Nearly one in five patients who responded within the first six months later lost that response despite continuing the drug, at a median of two years. Many regained control by adding mepacrine.

And nearly one in ten patients who did not respond in the first six months eventually did — after up to two years of continued treatment, or on rechallenge.

Six months is not long enough to call it a failure. That is a useful thing to know before abandoning a drug that half of people do eventually respond to.

The frequently quoted 55 percent response figure comes from a different study and rests on eleven patients. The 67 percent figure for adding quinacrine rests on fifteen. They are subgroup counts from an observational cohort, quoted as if they were trial results. Use the 200-patient number.

Practical snag worth naming: quinacrine, the standard rescue, is not commercially available through normal supply in the US or UK and requires compounding. The escalation strategy both studies rely on is one most patients cannot easily access.

Smoking, which is contested

The line is that smoking blocks antimalarials. The evidence is a meta-analysis of ten observational studies, 1,398 patients, pooled odds ratio for response in smokers of 0.53 — roughly half as likely to improve.

Upper confidence bound: 0.98. It only just clears significance. All ten studies were observational, smokers differ systematically from non-smokers in ways nobody adjusted for, and the authors state they could not run subgroup analyses by lupus subtype, by which antimalarial, or by dose. So there is no DLE-specific figure at all.

Then the prospective cohort that contradicts it. 218 patients, and at two to seven months, among those on antimalarials alone, current smokers improved more than never-smokers — median CLASI change of minus three against plus one. At eight months and beyond, on antimalarials plus another immunomodulator, current smokers did worse.

Most likely explanation is regression to the mean: smokers started with worse disease, median CLASI 9.5 against 7.0, so they had further to fall. Whatever the reason, an honest piece cannot present “smoking stops hydroxychloroquine working” as settled. Quitting is worth doing for about nine other reasons. This one is contested.

The newer agents, at their actual evidence level

Litifilimab, an antibody against BDCA2 on plasmacytoid dendritic cells, has the best data of the emerging drugs, and it is phase 2. 132 patients randomized across three doses and placebo. Differences from placebo in CLASI activity change at week 16 of minus 24.3, minus 33.4 and minus 28.0 percentage points, with a significant pre-specified dose-response model.

The sentence from the paper that the coverage left out: most of the secondary end points did not support the results of the primary analysis.

Note also that 150 mg outperformed 450 mg. Genuine dose-response does not usually look like that, and in a trial with arms of 25 and 48 patients it is the signature of noise. One case of herpes zoster meningitis four months after the last dose. The authors call for larger and longer trials.

Intralesional triamcinolone is universal practice for DLE and I could find no controlled trial data giving a response rate for it. Anyone quoting one is quoting consensus dressed as a number.

A round patch on the scalp is a biopsy

Not a course of antifungal shampoo, not a stronger conditioner, not six months of watching. A round scaly patch that is losing hair, in someone with pigmented skin, is the appointment.

The follicle is the clock. Inflammation reaching the stem cell compartment ends the possibility of regrowth, and no drug developed since has changed that. Everything else in this piece — the response rates, the smoking argument, the phase 2 antibodies — is happening downstream of whether anyone looked in time.

And the reason there is no delay literature for this disease is not that the delay does not exist. It is that nobody has run the study.

This article is educational and is not a substitute for care from someone who can look at your skin. Anything new, changing, painful or spreading should be assessed rather than researched.